Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan

NCT02747537 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Could not recruit participants for the study

Conditions

Pediatric Solid Tumors

Interventions

DRUG: Sorafenib
DRUG: Irinotecan

Sponsor

Washington University School of Medicine